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Abstract 
Immunotherapy using dendritic cells (DC) has shown promising results in clinical trials, but 
few relevant successes are recorded. Therefore, the choice of an appropriate DC population is 
critical for the outcome of this treatment. The DC used today in immunotherapy are often 
matured with a cytokine cocktail consisting of TNF-α, IL-1β, IL-6 and PGE2. These cells 
have deficits in their cytokine production, and also their migratory capacity in vivo needs 
improvement. After being introduced to bromelain and the effect it has shown on glioma 
cells, a curiosity about how it would affect DC maturation awoke. Bromelain is a pineapple 
stem extract that has been clinically used in adjuvant cancer treatment for a long time. The 
aim of this study was to analyze the effect of bromelain on DC maturation. 
Immature monocyte derived DC were stimulated for 24 h with different concentrations of 
bromelain and compared to cells stimulated with the cytokine cocktail. The phenotype of the 
generated cell populations was investigated by flow cytometry. Moreover, the 
phosphorylation patterns of MAP kinase proteins and AKT, in addition to nuclear RelB 
expression, were examined by Western blot. The migratory capacity of the generated DC 
populations was analyzed in a chemotaxis assay toward CCL19, and IL-12p70 production 
was determined by ELISA. The T cell stimulatory capacity of the generated DC populations 
was investigated by a mixed lymphocyte reaction (MLR).  
Bromelain treated DC showed a concentration dependent upregulation of maturation markers 
and co-stimulatory molecules. However, they had a less mature phenotype compared to DC 
stimulated with the cytokine cocktail. Phosphorylation patterns of MAP kinase proteins and 
AKT obtained from Western blotting indicated that bromelain stimulated DC were more 
similar to immature cells. Nuclear RelB expression of bromelain stimulated DC was lower 
compared to cytokine cocktail treated DC but higher compared to immature DC. All 
bromelain concentrations used in this study resulted in increased IL-12p70 secretion by DC 
compared to cytokine cocktail treated cells and immature DC. The chemotaxis assay revealed 
that nearly the same number of DC migrated without a chemokine gradient and the MLR 
revealed that bromelain stimulated DC can induce proliferation of allogeneic T cells 
comparable to DC treated with the cytokine cocktail.  
Although bromelain stimulated DC seem to be less mature than DC treated with the cytokine 
cocktail, they did produce more IL-12p70. Since lack of IL-12 secretion is one of the 
drawbacks of using the cytokine cocktail, bromelain might be used as an additional stimulus, 
in combination with other stimuli during generation of DC used in immunotherapy.
  Introduction 
1 Introduction 
 
1.1 Immune system 
The human immune system is an amazing instrument, defending our bodies from attacks 
caused by bacteria, microbes, parasites, viruses, toxins as well as dangerous cancer cells. The 
importance of this incredible system becomes clear when the consequences of death are 
considered. When death occurs, the immune system, in addition to all other functions of our 
body shuts down. The outcome of a non-functioning immune system is invasion of all 
possible infectious agents mentioned above, leading to decomposition of the body within 
weeks. This indicates how remarkable and essential the immune system is for our existence 
(1). The immune system consists of an innate and an adaptive immunity, and these two 
systems collaborate to generate a successful protection against all possible threats our bodies 
are exposed to. 
 
1.1.1 Innate immunity 
Innate immunity is the body’s first response to infectious agents or foreign antigens. This 
resistance is non-specific and does not create memory or lasting protection against pathogens. 
The innate immune system is the phylogentically oldest protection against infection and 
provides two main functions. First, the innate immunity is the body’s initial response and 
therefore attempts to prevent, control and eliminate infection or other threats. Second, the role 
of the innate immunity is to stimulate the adaptive immune response. Components of the 
innate immune response are (2): 
 
1) Epithelial barriers that function as a physical fence, preventing entry of pathogens. The 
skin, in addition to mucosal surfaces of gastrointestinal and respiratory tracts are the major 
epithelial barriers in the human body. 
2) The complement system consists of plasma proteins that circulate in the blood. These 
complement proteins are activated when they encounter microbes, eventuating in 
inflammation and destruction of the microbes. 
3) Phagocytes (neutrophils and macrophages) identify, ingest and break down microbes. 
Natural killer (NK) cells also contribute to elimination of microbes by similar mechanisms. 
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4) The last component is cytokines, which regulate and control the activity of immune-cells. 
Macrophages, neutrophils and NK cells produce and secrete cytokines that enable cell 
communication between inflammatory cells and responding tissue cells.  
 
Cells belonging to the innate immune response discover pathogens by recognizing patterns 
shared among pathogens through various pattern recognition receptors. These patterns include 
bacterial lipopolysaccharide (LPS) or teichoic acid, in addition to carbohydrates and viral 
RNA (3). There exist different classes of pattern recognition receptors, and the most 
comprehensive one is the family of toll-like receptors (TLR) (2). This family consists of 
eleven different TLR, named TLR 1 to 11. Some of these are located in the plasma membrane 
of the cells, while others are expressed in the endosomal membrane inside the cells. This 
enable the cell to recognize pathogens having already entered the cells, as well as those 
attacking from the outside. Several signaling pathways link signals received by TLR to 
transcription factors in the nucleus, and these transcription factors regulate expression of 
genes necessary for innate immune responses. 
 
1.1.2 Adaptive immunity 
The adaptive immune system is complementary to the innate immune system. Signals from 
the innate system activate the adaptive immune system, and an immune response is built in 
response to the signal. Since the immune response is developed after pathogen or antigen 
encounter, the adaptive response building up is specific towards these foreign substances. In 
addition, this response generates a memory that enables a more rapid and vigorous response to 
any repeated exposure.  
1.1.2.1 Humoral and cell mediated responses 
Adaptive immunity can be further divided into two types of responses, humoral immunity and 
cell-mediated immunity. These two responses are executed by different components of the 
immune system, and they destroy different kinds of microbes. The humoral immunity consists 
of antibodies. Antibodies are produced by B lymphocytes and they remove microbes by 
recognizing microbial antigens and target these microbes for degradation. This is partly 
achieved by the help of the complement system, which is a part of the innate immune system. 
The humoral immune response is the mechanism against extracellular microbes and the toxins 
these secrete. The other immune response, the cell-mediated response, is mediated by T 
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lymphocytes. This immune response is directed toward intracellular microbes like virus and 
some bacteria since these are inaccessible for antibodies in the blood. There exist two types of 
T lymphocytes, helper T lymphocytes that activate and help macrophages and other immune 
cells to kill phagocytosed microbes, and cytotoxic T lymphocytes (CTL) which kill infected 
cells to eliminate reservoirs of infection. 
1.1.3 Linking innate and adaptive immunity through antigen presenting 
cells 
To eliminate foreign substances, the innate and adaptive immune systems need to collaborate. 
This is necessary since the innate immunity often can not combat an infection alone, and the 
adaptive immunity is dependent on signals from the innate system to be activated. The 
bridging between these two responses is chiefly executed by antigen presenting cells (APC). 
The function of APC is to capture antigens, which they then transport and display to cells of 
the adaptive immune system. Dendritic cells (DC), B lymphocytes, and macrophages are all 
noted as professional APC because they are capable of activating T cells. Although all these 
cells have this ability, DC are superior concerning T cell stimulation, because of their ability 
to stimulate naïve T cells This has been confirmed by mixed lymphocyte reactions (MLR) 
where the T cell stimulatory capacity of these different APC have been compared (4).  
1.1.4 Dendritic cells 
DC are of crucial importance in our immune responses. They are the sentinels of the immune 
system, and have the function of bridging the innate and the adaptive immunity. 
DC have been named according to their physical appearance, which is characterized by large 
amounts of long, membranous extensions on the cell surface. They have the role of capturing 
antigens and display these to the lymphocytes of the adaptive immune response. This 
interaction between a DC and a lymphocyte is demonstrated in figure 1.1 (A), where the 
characteristic appearance of DC is visualized. Figure 1.1 (B) shows schematically how this 
interaction takes place. Several co-stimulatory molecules and adhesion proteins are required 
for activation of the T cell. In addition, peptides presented by APC to T cells need to be 
coupled to MHC molecules.  
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Figure 1.1: Interaction between DC and lymphocytes. The connection between a DC and a lymphocyte are 
shown in (A), the characteristic appearance of DC with its membranous projections are also visualized. (B) 
shows the different molecules involved in antigen presentation between a DC and a T cell. T cell ability to 
recognize peptides presented by APC requires the peptides to be displayed in connection with MHC proteins on 
the APC. In addition co-stimulatory and adhesion molecules are necessary for activation of the T cell. Figure A 
from: www.bcrfund.org/Story006.htm, and figure B from: www.homepages.ucl.ac.uk/~ucbpdsb/Essay2/TCR-
MHC.jpg  
 
 
DC are complex immune cells and they exist in immature and mature states. Immature DC are 
the sentinels that patrol the periphery, seeking antigens to capture. After immature DC have 
been exposed to an antigen and have captured this, they migrate to lymphoid organs where 
they present these antigens to naïve T lymphocytes. During this journey to the lymphoid 
organs, the DC mature and start presenting antigens instead of capturing them. Without the 
ability of DC to migrate, naïve T lymphocytes would not be able to achieve contact with 
peripheral antigens (5).  
 
1.1.4.1 DC origin and subsets 
Immature DC are continuously produced in the bone marrow from hematopoietic stem cells 
(6). DC can be generated ex-vivo from blood monocytes when cultured with appropriate 
cytokines (7). Since the DC population in the blood is a very small population, this method 
enables generation of higher numbers of DC. 
There exist two main lineages of DC, myeloid DC (mDC) and plasmacytoid DC (pDC) (8). 
These two lineages have different morphology, function and expression of markers. Despite 
these differences, the two DC lineages express the same adhesion-, co-stimulatory-, and 
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inhibitory molecules, in addition to activation markers (9). The mDC can be found almost 
everywhere in the body. Some are located in peripheral tissues, others are found in secondary 
lymphoid organs, while a few mDC also circulate in the blood. These are the ones that handle 
pathogen entry in the skin and mucosal tissue. The pDC all circulate in the blood, and from 
here they can enter the T cell areas in the lymphoid organs through high endothelial venules. 
These DC may become specialized to capture blood borne pathogens in addition to recognize 
self-antigens (8, 9).  
Langerhans cells (LC) are a subset of mDC. They reside in the epidermis and are involved in 
the immune response toward several different infections (skin transmitted viral, bacterial and 
parasitic), dermatoses and skin cancers. LC were discovered in 1868, but they were not 
connected to the DC system until Steinman and Cohn around 100 years later identified splenic 
DC (8, 10). DC consist of a number of different lineages and subsets and are therefore a 
heterogeneous cell population. Still there is a lot unknown about the DC subsets and their 
classification. However, it is clear that DC reside in many areas of the body where they carry 
out antigen capture and subsequent presentation to lymphocytes, and they are a necessity to 
achieve high-quality immune responses.  
 
1.1.4.2 Antigen capture, processing and presentation 
Immature DC can capture antigens using several pathways. First they can utilize phagocytosis 
to take up particles and microbes, second they can internalize extracellular fluid and solutes 
by micro- and macro-pinocytosis. (11, 12). The third mechanism of DC antigen uptake is 
receptor mediated endocytosis. DC express a number of different receptors that mediate this 
function of antigen capturing, including C-type lectin receptors and Fcγ and Fcε receptors (3, 
12). The fourth manner DC can pick up antigens is through engulfment of apoptotic bodies 
(13, 14). Immediately after antigen uptake immature DC undergo a change that leads to 
maturation of the cells. This change involves reduction of the ability to capture antigens and 
upregulation of major histocompatibility complex (MHC) molecules and other surface 
molecules necessary for T-cell priming (5, 12). While B lymphocytes can recognize antigens 
directly through their B-cell receptors, T lymphocytes are dependent on antigen processing 
and presentation mediated by an APC. This is necessary since the T cell receptors (TCR) lack 
the ability to recognize antigens directly. Instead the TCR recognize antigen peptides bound 
to MHC molecules (12). DC are the most effective APC since they are able to produce larger 
amounts of MHC class II peptide complexes compared to other types of APC (15). 
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One mechanism of antigen processing by DC is done in endosomes. Generated peptides are 
transported to MHC class II-rich compartments (MIIC) residing inside DC. MIIC are late-
endosomal structures where antigen peptides are connected to MHC clas II molecules (12). 
The peptide loaded MHC class II molecule is then transported to the plasma membrane (9).  
There exist two types of MHC molecules. MHC class II molecules present peptides to CD4+ 
helper T cells while peptides presented on MHC class I molecules stimulate CD8+ CTL. 
Antigens to be presented on MHC class I molecules are ubiquitinated and then degraded by 
the proteasome before they are transported as peptides to the endoplasmic reticulum (ER). 
MHC class I molecules are loaded with peptides directly in the ER where they are synthesized 
(3, 12). Peptide loaded MHC class I molecules move through the golgi apparatus and are 
transported to the cell surface by exocytic vesicles. Both processes of peptide coupling to 
these MHC molecules are shown in figure 1.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Processing and presentation of MHC class I and MHC class II peptides. Antigens captured are 
processed and then coupled to either MHC class I or MHC class II molecules. The right part of the figure shows 
how intracellular antigens are bound to MHC class I molecules. These antigens are ubiquitinated and degraded 
by the proteasome before linked to the MHC proteins in the ER. This complex is then transferred to the cell 
surface where the peptide is presented to CD8+ T lymphocytes. The left side of the figure explains how 
extracellular antigens are processed into peptides in phagolysosomes, before transported to MIIC where they are 
bound to MHC class II molecules. These peptide-MHC complexes are transferred to the cells surface where they 
are recognized by CD4+ T lymphocytes. Figure from Garland Science 2005. 
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1.1.4.3 Maturation of DC 
At the same time as antigens are processed and coupled to MHC molecules, other changes 
also occur with the DC. Immediately after antigen capture, the maturation process begins. 
While immature DC have the ability to capture antigens, only mature DC have the ability to 
present antigens and prime immune responses (16).  
 
During maturation DC start expressing new molecules on the surface while others are 
removed. Mannose receptor (CD206), Fcγ receptor (CD32) as well as the C-type lectin DC-
SIGN (CD209), all involved in antigen uptake, have shown reduced expression on DC that 
have been stimulated and matured (17). MHC class II molecules and co-stimulatory 
molecules like CD40, CD80 and CD86 are upregulated on stimulated DC. The receptors of 
these co-stimulatory molecules are present on T cells, and the connections between these are 
required for T cell commitment (3, 5). In addition to these molecules, CCR7 is rapidly 
expressed on matured DC, and this chemokine receptor directs DC migration into the lymph 
nodes where DC release cytokines and chemokines that attract T and B cells (6, 9, 12).  
 
Mature DC also enhance adaptive immune responses by synthesizing high levels of IL-12 
(12), resulting in a stronger CTL response due to IL-12 activation of Th1 cells and the ability 
of these helper cells to induce proliferation of CTL. (18). Maturation signals also induce 
phosphorylation of mitogen-activated protein kinases (MAPK) in DC. There exist several 
MAPK signaling pathways, and they are activated through a cascade of phosphorylated 
kinases. When they are phosphorylated they gain the ability to act on downstream targets. As 
reviewed by Nakahara et al, studies have implied that MAPK signaling pathways regulate 
several parts of DC maturation, including phenotypic and functional maturation as well as 
cytokine production (19).  
 
1.2 Tumor immunology 
Tumor formation and cancer development is the result of a long chain of events. It is known 
that environmental factors such as chemicals and radiation can cause mutations resulting in 
cancer development. Other factors contributing to development of cancer and tumors include 
viral infection or genetic predisposition.  
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If a foreign antigen is discovered by cells of the immune system, it will initiate an immune 
response that leads to removal of affected cells and the pathogen. The immune system is 
capable of executing this because the antigen or pathogen is recognized as foreign. One of the 
problems concerning immune responses toward tumors is that some tumor antigens are 
recognized as self antigens by T cells. This will lead to destruction and removal of these T 
cells to avoid autoimmune reactions. These evasions from the immune response can occur 
since cancer cells are derived from normal cells and have been altered due to mutations. This 
mechanism known as tolerance is necessary to avoid the immune system attacking the body’s 
own cells. Fortunately this is not true for all tumor antigens. Many tumor antigens have been 
shown to be recognized by the immune system as foreign or altered-self and thereby activate 
an immune response (20, 21).  
 
This is not the only manner tumors use to evade the immune system. Many tumor cells lack or 
manage to loose tumor specific antigens. In addition to tumor specific antigens, also MHC 
class I has been shown to be deficient on cancer cells. Without MHC class I, cells of the 
immune system loose the ability to recognize tumor antigen presented on the surface of the 
cell and initiate immune responses (22).  
Tumors also induce the generation of blocking factors and tumor specific regulatory T cells 
(Tregs). These inhibit interactions between effector cells and cancer cells (22). Tregs are a 
subpopulation of T lymphocytes, and these maintain system homeostasis in addition to 
tolerance by suppressing the activation of the immune system. The presence of Tregs in 
tumors is linked with reduced tumor specific immune responses, and poorer survival rates 
(23).  
Defects in effector cells are also a problem concerning immune responses toward tumors. 
Tumor cells produce immunosuppressive molecules that affect the effector cells negatively. 
As a result, macrophages and natural killer (NK) cells loose their phagocytic ability and 
cytotoxity (22).  
In addition to producing these immunosuppressive molecules, tumor cells also secrete soluble 
products that directly affect the function of immune cells. Vascular endothelial growth factor 
(VEGF) is one of the soluble factors secreted from tumor cells. In addition to its role in 
angiogenesis, VEGF has been shown to inhibit the functional maturation of DC. It was 
discovered that DC cultured in the presence of tumor cell supernatants had a significant 
reduction in their stimulatory capacity. This was confirmed when the cells were analyzed in 
an allogeneic MLR (24). Transforming growth factor beta (TGF-β) and interleukin (IL)-10 
 14
  Introduction 
 
have also displayed a clear role in immune suppression. TGF-β is important in several cell 
functions; in addition it stimulates angiogenesis and suppresses the effect of the immune 
system. Cancerous cells often have increased TGF-β secretion. IL-10 is an immunoregulatory 
cytokine, and is known to target APC. It directly promotes tumorigenesis by affecting tumor 
cells, while it indirectly suppresses immune responses. The relative mRNA expression of 
VEGF, TGF-β and IL-10 in tumor tissue was compared with tumor free tissue, and it was 
shown to be frequently overexpressed in the tumor tissue (25).  
 
1.3 Tumor immunotherapy 
Tumor immunotherapy aims at activating the body’s own immune system to fight the tumor. 
Therefore immunotherapy may not lead to as many negative side effects as conventional 
cancer treatments do by being more targeted to the cancer cells. Chemotherapy aims at 
eliminating cancer cells by killing rapidly dividing cells, while radiation therapy uses ionizing 
radiation to kill cancer cells and shrink tumors. Unfortunately it is not possible to direct this 
treatment specifically to cancer cells. The consequence is cell death also among healthy cells. 
This results in hair loss, nausea and leukopenia which affect the physical and mental 
wellbeing for the patient. 
Immunotherapy can be either passive or active. Passive immunotherapy provides extra 
supplies to the immune response by use of antibodies or CTL. The disadvantage regarding 
passive immunotherapy is the short lived response. Since all components introduced have 
short half-lifes the treatment must be repeated to achieve desirable results. Active 
immunotherapy directly activates the immune system in the patient, by triggering 
proliferation and activation of residing T cells. Active immunotherapy therefore aims to 
achieve an endogenous immune response, where the immune system recognizes the tumor as 
foreign. 
 
1.3.1 DC in tumor immunotherapy 
Since DC are the most potent APC, many scientists designing or improving 
immunotherapeutic treatments are interested in DC. Increased understanding of the 
importance of DC in immune responses and their physiology has lead to optimism concerning 
their capacity in immunotherapy (26). In addition to generating a potent anti-tumor response 
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through activation of T cells, DC have also shown to be competent to directly eliminate 
cancer cells through expression of death receptor ligands (27).  
This indicates that DC are interesting in multiple ways concerning cancer treatment and tumor 
elimination. DC in immunotherapy are utilized both by activation of DC in vivo, and by 
reinfusion of ex vivo generated DC. Methods stimulating DC inside the body are noted as in 
vivo techniques. One of the aims for in vivo approaches is to expand the DC pool in the 
patient since some patients have a lowered frequency of activated DC. Injections of DC 
specific growth factors such as granulocyte-macrophage colony-stimulating factor (GM-CSF), 
FMS-like tyrosine kinase 3 ligand (Flt3-L), granulocyte colony-stimulating factor G-CSF or 
CD40 ligand (CD40-L) can increase DC numbers and make the DC present tumor antigens in 
a more effective way (28-30). Another method tested in mouse models is engineering of 
tumor cells. Attempts where tumor cells have been transfected with co-stimulatory molecules 
from the B-7 and the TNF/TNF-R family, and MHC class II molecules have been performed, 
hoping to make the tumor cells express DC functions. By doing this, scientists desire to 
enhance the tumor antigen presentation by engineering the tumor cells to directly activate 
CD4+ or CD8+ T cells (28, 31). 
1.3.1.1 Ex vivo approaches 
In addition to the two main lineages of DC, there is one more population of DC, monocyte 
derived DC. After several years searching it was found that monocyte derived DC actually 
exist in the body. During an inflammation, monocytes in the blood are transformed into 
monocyte derived DC. Since DC are a rare cell population in the blood, this is today an 
established method exploited by scientists to generate large quantities of DC in cell culture. 
Monocytes are isolated from human blood, and by correct stimulation they will develop into 
DC over a period in cell culture. In theory tumor immunotherapy using ex vivo generation of 
DC is simple and executable, but unfortunately it is not that easy.  
Figure 1.3 gives an overview of this method. Blood cells are harvested from the patient and 
peripheral blood mononuclear cells (PBMC) are isolated by density gradient centrifugation. 
Immature DC are generated from the monocytes in the PBMC. These cells are then pulsed 
with tumor material from the patient. This in addition to other stimulations results in matured 
DC that present tumor specific antigen. This other stimulation induces a functional maturation 
of DC, and this is important for the ability of the cells to generate strong immune responses 
when they are transferred back into the patient. In theory the cells will migrate from injection 
site to the lymph nodes, where they present the tumor antigen to lymphocytes and initiate an 
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immune response toward the tumor. Since the quality of the maturation stimulus is essential 
for proper immune responses, improvement of this is the aim of my project. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: DC vaccination strategy. Blood cells are harvested and PBMC isolated. From the monocytes, 
immature DC are generated ex-vivo. These cells are stimulated to mature, and presented to tumor material from 
the patient before they are transferred back into the patient. DC will then migrate to lymph nodes where they 
interact with T lymphocytes and induce immune responses toward the tumor. Figure made by Arnt-Ove Hovden. 
 
 
Several phase I studies using ex vivo generated DC have been carried out in humans, 
unfortunately, only few of these early trials have shown significant tumor regressions (32-34). 
Few phase III studies have been carried out using DC vaccines so far. One approach to 
investigate DC vaccination versus standard Dacarbazine (DTIC) treatment in stage IV 
melanoma was conducted between March 2000 and July 2003 (35). In this phase III trial, 
patients were divided into two groups. One of the groups received DTIC which is the standard 
first-line treatment given to metastatic melanoma patients. The other group received a DC 
vaccine. DC used in this vaccine was matured with a cytokine cocktail consisting of TNFα 
(10 ng/ml), IL-1β (2 ng/ml), IL-6 (1x103 IU/ml) and PGE2 (1 µg/ ml), and then loaded with 
several MHC class I and II restricted peptides. No significant difference was shown between 
the two groups, and the study was ended after the first interim analysis due to low objective 
response in both groups (DTIC: 5,5%, DC: 3,8%) (35).  
These results show that improvements of the DC vaccine still are necessary, although one of 
the main obstacles concerning these trials is that the patients used are all late-stage cancer 
patients. The result of this is that the patients already have an enormous tumor burden, and are 
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immunosuppressed by heavy use of conventional cancer therapies and therefore may not be 
able to develop a strong immune response.  
Another issue hampering the success of DC vaccination is lack of knowledge concerning 
tumor antigens and antigen loading. Furthermore, to be able to initiate a response against the 
tumor, the DC injected back into a patient need to possess the ability to migrate from injection 
site to lymph nodes. Research has shown that mature DC have a superior migration capacity 
compared to immature DC (36). One possible explanation can be that mature DC upregulate 
the expression of chemokine (C-C motif) receptor 7 (CCR7). There is evidence confirming 
that this G-protein coupled receptor participates in the migration of DC from peripheral tissue 
to lymph nodes (37). The migratory pattern for mature DC still requires more investigation, in 
that way generated DC can be improved to fit the requirements necessary for successful 
migration. Obviously more research is necessary to develop a successful ex vivo generated 
DC vaccine.  
Also the maturation step during generation of mature monocyte derived DC needs 
improvement. DC used today are stimulated with a “gold standard” cytokine cocktail 
consisting of TNFα, IL-1β, IL-6 and PGE2, however this stimulation is not optimal. PGE2 is 
supposed to induce and improve the migration of the cells, but has in addition the effect of 
inhibiting IL-12 secretion by the DC (38). Since IL-12 is an important stimulator for T cell 
activation, the stimulation used needs to be improved to be able to generate strong immune 
responses. 
 
1.4 Aim of the study 
The aim of this study was to analyze the effect of bromelain on DC maturation, concerning 
their phenotype, cytokine production and T cell stimulatory capacity. Bromelain is a 
pineapple stem extract, prepared from cooled pineapple juice by centrifugation, ultrafiltration 
and lyophilisation (39). Immunological and enzymological data indicate that crude pineapple 
stem extracts contain four different cysteine proteinases. These are stem bromelain, ananain, 
comosain and fruit bromelain. Of these, stem bromelain is the major component (40). 
Bromelain has been clinically used as additive to cancer treatment to reduce side effects of 
chemotherapy, and to reduce inflammation and edema as well as improve wound healing 
caused by radiotherapy and surgery (39, 41). Previous studies have shown that bromelain 
treated glioma cells have a significant reduction of adhesion, migration and invasion capacity 
without affecting the cells’ viability (42). In addition, adhesion molecules on blood and 
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endothelial cells are known to change function after exposure to bromelain, and bromelain has 
shown to activate various immune cells and their cytokine production (39). 
  Materials 
2 Materials 
 
2.1 Equipment        
Name        Company  
Biological Safety Cabinet class II    Nuaire, USA 
CASY cell counter      Schärfe System, Germany 
Centrifuges       - KUBOTA 8700, Tokyo, Japan
        -Thermo Heraeus multifuge 1S-R 
        - Mini-spin, Eppendorf, Germany 
- Thermo Heraeus Fresco 17, USA  
ChemiDoc       BIO-RAD 
Microplate reader, EMax     Molecular Devices 
Flowcytometer: BDFACS Canto    BD Bioscience, USA 
CO2 Incubator       Forma Scientific, USA 
Microscope: Leica DMIL     Leica, Germany 
Mini-PROTEAN MP3 system    BIO-RAD, USA 
Wather bath       GFL, Germany 
 
2.2 Plastic ware      
Name        Company 
6 well plate      NUNC, Denmark 
96 well cell culture plate      NUNC, Denmark 
96 well V-shaped plate NUNC, Denmark 
Cryotubes 1ml/2ml NUNC, Denmark 
Microtubes 1.5ml clear      Axygen 
HTS Transwell 96 system      Corning, USA 
T25 Cell culture flask      NUNC, Denmark 
T75 Cell culture flask      NUNC, Denmark 
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2.3 Software 
Name        Company 
FlowJo       Tree Star, Inc 
Prism        GraphPad Software 
Soft Max Pro       Molecular Devices 
Quantity One       BIO-RAD, USA 
    
2.4 Buffers and media        
Name    Composition 
10x TBS   0.1 M Tris pH 8.0 
    1.4 M NaCl 
1x Blotting buffer  1x Running buffer without SDS 
    20% Methanol 
1x Running buffer  0.1% SDS 
    25 mM Tris 
    192 mM Glycine 
1x TBST (0.5%)  100 ml 10x TBS 
    5ml Tween20 
    900 ml H2O 
6x Lämmli buffer  375 mM Tris HCl pH 6.8 
    9% SDS 
    50% Glycerol 
    9% β-Mercaptoethanol 
0.03% Bromphenolblue 
Blocking buffer  5 % milk in 1xTBST (0.5%) 
Buffer A (Nuclear extracts): 10 mM HEPES pH 7.9 
10 mM KCl 
0.1 mM EDTA 
0.1 mM EGTA 
+ freshly added before use: 
1 mM DTT  
0.5 mM PMSF 
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Buffer C (Nuclear extracts): 20 mM HEPES pH 7.9 
0.4 M NaCl 
1 mM EDTA 
1 mM EGTA 
+ freshly added before use: 
1 mM DTT 
1 mM PMSF 
FACS buffer   PBS + 0.5% BSA 
PBS pH 7.4   137 mM NaCl 
    2.7 mM KCl 
    8.1 mM Na2HPO4 
    1.5 mM KH2PO4 
RIPA buffer   50 mM Tris pH 7.4 
    1% NP40 
    0.25% Na-deoxycholat 
    150 mM NaCl 
    1 mM EDTA 
    + freshly added before use: 
    1x proteinase inhibitor complete  
    1 mM PMSF 
    1 mM Na-orthovanadat 
    1 mM NaF 
RP10 medium   RPMI 1640 w/ ultraglutamine 
    10 % FBS 
    50 units/ml Penicillin sodium 
    50µg/ml Streptomycin sulfate in 0.85% saline 
Stripping buffer   2% SDS 
    62.5 mM Tris/HCl pH 6.7 
    100 mM β-Mercaptoethanol 
Washing buffer  0.05% Tween20 in PBS 
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2.5 Reagents       
Name        Company 
0,5M Tris-HCl pH 6,8     BIO-RAD 
1,5M Tris-HCl pH 8,8     BIO-RAD 
25x Proteinase inhibitor, complete EDTA-free  Roche, Germany 
Acrylamide 30%      BIO-RAD, USA 
Albumin, bovine serum (BSA)    Sigma Aldrich, USA 
Ammonium persulfate (APS)    BIO-RAD, USA 
β-Mercaptoethanol >=99%     Sigma Aldrich, USA 
Casy ton       Innovatis, Germany 
CCL19       Immunotools, Germany 
Dimethyl sulfoxide (DMSO)     Sigma Aldrich, UK 
Ethylenediaminetetraacetic acid (EDTA) 0.5 M  Sigma Aldrich, USA 
Glycine        BIO-RAD, USA 
GM-CSF       Immunotools Germany 
Ionomycin       Sigma Aldrich, USA 
IL-1β        Strathman Biotec, Germany 
IL-4        Immunotools, Germany 
IL-6        Immunotools, Germany 
Isopropanol prima      Arcus, Norway  
Lymphoprep       Axis-Shield, Norway 
Methanol       MERCK, Germany  
Milk powder       Frema, Germany 
NaF         MERCK, Germany 
NaOrthovanadat       MERCK, Germany 
Phorbol 12-myristate 13-acetate (PMA)   Sigma Aldrich, USA  
Penicillin/streptomycin     Invitrogen, USA 
PGE2        Sigma Aldrich  
PMSF         Roche, Germany 
Ponceau S       Sigma Aldrich, USA 
Precision Plus Protein Standard    BIO-RAD, USA 
RPMI 1640 with ultraglutamine 1    BioWhittaker, Belgium 
Sodium dodecyl sulphate (SDS)    BIO RAD, USA 
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Tetramethylethylenediamine (TEMED)   BIO-RAD, USA 
TNFα        Immunotools, Germany 
Tris        BIO-RAD, USA 
Tween 20       MERCH, Germany 
X VIVO 20 Serum free hematopoietic cell medium  Biowhittaker, Belgium 
 
2.6 Kits       
Name        Company 
BCATM Protein Assay Kit     Pierce, USA 
BD Compbeads      BD Biosciences, USA 
ELISA MAXTM Set Deluxe Human IL-12p70  BioLegend, USA 
Immunstar WesternCTM kit     BIO-RAD, USA 
Vybrant CFDA SE, Cell Tracer kit     Invitogen, USA 
 
2.7 FACS Antibodies 
Name     Clone   Company 
CCR7-PE     150503  R&D Systems, USA 
CD1a-PE     NA1/34-HLK  AbD Serotec, Germany 
CD14-FITC     UCHM1  AbD Serotec, Germany 
CD38-Alexa Fluor 647   AT13/5  AbD Serotec, Germany 
CD4 APC     MEM-241  Immunotools, Germany 
CD40-FITC     LOB7/6  AbD Serotec, Germany 
CD8 PE    LT8   AbD Serotec, Germany 
CD80- APC     MEM-233  Immunotools, Germany  
CD83-PE     HB15e   AbD Serotec, Germany 
CD86-FITC     BU63   AbD Serotec, Germany 
CD91-PE     A2Mr alpha-2  AbD Serotec, Germany 
HLA-DR-APC   HL-39   AbD Serotec, Germany 
IgG APC    PPV-06  Immunotools, Germany  
IgG FITC    PPV-06  Immunotools, Germany 
IgG PE    PPV-06  Immunotools, Germany  
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2.8 Western Blot Antibodies      
Name     Clone    Company 
AKT (Pan)    C67E7    Cell Signaling, USA 
Phospho-AKT    D9E    Cell Signaling, USA 
P44/42 MAP     137F5     Cell Signaling, USA 
Phospho-P44/42 MAP    9101    Cell Signaling, USA 
P38 MAPK     9212    Cell Signaling, USA 
Phospho-p38 MAPK    3D7    Cell Signaling, USA 
SAPK/JNK     56G8    Cell Signaling, USA 
Phospho-SAPK/JNK    81E11    Cell Signaling, USA 
Goat anti-rabbit (HRP)      BIO-RAD, USA 
RelB     SC-226   Santa Cruz 
TFIID (TBP)    SC-273   Santa Cru
  Methods 
3 Methods 
 
3.1 Generation of monocyte derived DC 
The generation of monocyte derived DC requires several steps. First PBMC were isolated 
from buffy coat blood. Then the monocytes were isolated from the PBMC by plastic 
adherence. The monocytes were then cultured and stimulated to become immature DC, before 
these cells could be stimulated to develop into mature DC. 
 
3.1.1 Isolation of PBMC 
The bag containing buffy coat blood was poured into a T75 cell culture flask. The amount of 
blood from a buffy coat bag is roughly 50ml, and this was diluted approximately 1:4 with RT 
PBS up to 130 ml. 12 ml lymphoprep were added to four 50 ml tubes, and 33 ml of diluted 
blood were carefully layered on top of the lymphoprep on each tube. The four tubes were 
centrifuged for 30 min and 23°C at 800g with no brake. After centrifugation, the PBMC were 
visible as a white band of cells between the lymphoprep and the plasma. PBMC were 
transferred from the four tubes into two new 50ml tubes. Cold PBS was added up to 50ml and 
centrifuged for 5 min and 4°C at 400g. PBMC were then washed 2-3 times with cold PBS and 
centrifugation for 5 min and 4°C at 400g. The supernatant was removed and pellet was 
resuspended in 10 ml RP10 medium. 
 
3.1.2 Ex-vivo generation of DC 
PBMC were transferred to T75 cell culture flasks, approximately 1x108 cells in each flask and 
10 ml in total volume. First RP10 medium was added into the flasks, and then the PBMC 
were transferred. Flasks were incubated 1 h in a humidified incubator at 37°C, 5% CO2. After 
1 h incubation monocytes had attached to the surface of the flasks. Non-adherent cells were 
collected in the medium before 10 ml RT PBS were added to each flask to wash and remove 
non-adherent cells other than monocytes. This wash procedure was repeated 1-2 times until 
few flowing cells remained. Then there were added 10 ml of RP10 medium containing 20 
ng/ml IL-4 and 100 ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF) to 
each flask before they were incubated for 6 days in a humidified incubator at 37°C, 5% CO2. 
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This stimulation develops the monocytes into immature DC. Every 2-3 days of incubation 
new cytokines were added directly to the flasks, at the same concentrations as before. 
 
3.1.3 Maturation of DC  
Immature DC were harvested from all T75 flasks on day 6. Cells were detached by pipetting 
medium up and down a few times before transferred to new tubes. Remaining cells were 
washed loose with ice-cold PBS w/2 mM EDTA, and this used PBS that contained remaining 
DC were collected into tubes. Washing steps were repeated 1-2 times until all cells were 
collected. 
 
When all cells were detached and transferred to tubes, tubes were centrifuged for 5 min and 
4°C at 400g. The conditioned RP10 medium was collected for further use and PBS wash 
supernatant was removed. Pellets were dissolved in cold PBS, collected into one tube and 
centrifuged again for 5 min and 4°C at 400g. Washing procedure was repeated before pellet 
was resuspended in 5 ml of the conditioned RP10 medium and counted. Cells were then 
transferred to six well plates, 1,5x106 cells/ well, total volume in each well was 2 ml. To 
induce maturation of DC, incubation with different cytokines is required. In addition to IL-4 
(20 ng/ml) and GM-CSF (100 ng/ml), TNFα (10 ng/ml), IL-1β (10 ng/ml), IL-6 (1x103 IU/ml) 
and PGE2 (1 µg/ ml) were added.  
 
Since I was testing how bromelain affects the maturation of DC, different concentrations of 
bromelain were added in addition to IL-4 and GM-CSF instead of the cytokine cocktail. 
 
Calculated amount of medium were added to the wells before 1 ml of the cell suspention were 
transferred to each well. After this, the calculated volume of bromelain and cytokines were 
added. Wells containing immature cells that were supposed to stay immature only received 
IL-4 and GM-CSF. The cells were then incubated in a humidified incubator for 24h at 37°C, 
5% CO2. 
 
 
 
 
 
 27
  Methods 
Table 3.1: Maturation stimuli of DC 
DC population Cell suspension * Bromelain ** 
(Stock 1 mg/ml)  
Medium *** 
Immature DC 1,5x106  1 ml 
Cytokine DC 1,5x106  1 ml 
Bromelain (50 µg/ml) 1,5x106 100 µl 0,9 ml 
Bromelain (25 µg/ml) 1,5x106 50 µl 0,95 ml 
Bromelain (10 µg/ml) 1,5x106 25 µl 0,975 ml 
Bromelain (5 µg/ml) 1,5x106 5 µl 0,995 ml 
 
* Each well was added 1,5x106 cells in 1 ml. ** The amount of bromelain used. *** Volume of medium added 
to achieve a 2 ml total of RP10 medium. 
 
3.1.4 Harvesting of DC 
The different cell populations were checked and compared for morphological distinctions 
using a microscope before the cells were harvested and transferred to 15 ml tubes and 
centrifuged for 5 min and 4°C at 400g. Ice-cold PBS w/ 2 mM EDTA was added to each well 
and wells were checked in themicroscope for adherent cells. These remaining cells detached 
as a consequence of the ice-cold PBS w/EDTA repeatedly pipetted. 
After centrifugation supernatants from all cell populations were collected, aliquoted and 
stored at -20°C in eppendorf tubes for later analyses.  
 
Pellet was resuspended using the PBS from the wells, and new ice-cold PBS w/EDTA were 
added to the wells to collect the last part of remaining cells. This PBS was also collected into 
the tubes with cells, before all cells were centrifuged for 5 min and 4°C at 400g. After 
centrifugation the pellet was resuspended in RP10 medium and counted. 
 
3.2 Standard-FACS for DC 
Flow cytometry allows to measure properties of individual cells. The machine analyzes one 
cell at the time as they pass through a laser beam and cause light to scatter and fluorescent 
dyes to emit light at different frequencies forward scatter channel (FSC) indicates the size of 
the cells while the side scatter channel (SSC) shows the granularity of the analyzed cells. 
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These parameters are used to distinguish between different living cells and cellular debris. By 
staining cells with fluorochrome conjugated antibodies it is among other things possible to 
investigate the phenotype of the cells. Both molecules on the cell surface and targets in the 
cytoplasm can be analyzed with this method.  
 
After the cells were harvested and counted, 5x105 cells in 250 µl FACS-buffer were 
transferred into a 15 ml tube. First FcReceptor block was added to the cells (2,5 µl/5x105 
cells) and incubated at RT while antibodies were prepared in a 96 well plate. Cells used for 
phenotype analyses were stained with FITC, PE or APC conjugated mAb specific for CD14, 
CD1a, HLA-DR, CD83, CD80, CD86, CD40, CCR7, CD38 and CD91. As a control FITC, 
PE and APC conjugated mouse IgG was used. Antibodies were prepared in master mixes and 
distributed to wells before 50 µl cell suspension (1x105cells) were added to each well. For the 
compensation and negative control, 20 µl beads were added. After cell suspension was added, 
cells and antibodies were incubated for 10 min in the dark at RT. Then 150 µl FACS buffer 
were added to each well and the plate was centrifuged 5 min and 4°C at 400g. The 
supernatant was removed and new FACS-buffer was used to dissolve pellets before 
centrifugation was repeated. The cells were then resuspended in 150 µl FACS buffer and 
transferred to small FACS tubes for flow cytometry analysis.  
 
3.3 Western blot 
Western blot was performed with both protein lysates and nuclear extracts. Remaining cells 
after the different analyses had been performed were used for protein lysate. Amount of 
proteins in the lysate was later determined by a BCA assay. For SDS-PAGE a 12% gel was 
used, and after gel electrophoresis, proteins were transferred onto a membrane by Western 
blotting. To be able to detect more than one protein of similar size, the membranes were 
stripped. 
3.3.1 Preparation of protein lysate 
Cells were washed with PBS and transferred to eppendorf tubes and centrifuged for 10-30s at 
12100g. All supernatant was carefully removed and pellet was dissolved in freshly prepared 
radio-immuno-precipitation assay (RIPA) buffer (approx.100µl/1x106 cells), followed by 10 
min incubation on ice. The lysates were then centrifuged for 5 min and 4°C at 17000g. The 
supernatant containing the proteins was transferred to a new pre-cooled eppendorf tube on ice, 
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and 5µl of the lysate was transferred to a second pre-cooled eppendorf tube for future BCA 
assay analysis. The BCA aliquot was placed at -20°C and the protein lysate was placed at -
80°C. 
 
3.3.2 Preparation of nuclear extracts 
Cell suspension containing 5x105 cells were transferred to 15 ml tubes and filled with 10 ml 
Tris buffered saline (TBS). Cells were then centrifuged for 5 min and 4°C at 400g and the 
pellet was dissolved in 1 ml TBS, transferred to eppendorf tubes and centrifuged for 15 s at 
12100g before the supernatant was carefully removed. Nuclear extracts were prepared 
according to the protocol described by Schreiber et al (43). The pellet was dissolved in 400 µl 
cold buffer A and incubated 15 min on ice. Then 25 µl 10% NP-40 solution was added and 
sample was vortexed for 10s before it was centrifuged 30s at 17000g. Supernatants containing 
cytoplasm and RNA were collected into new pre-cooled tubes and placed at -80°C. Pellet was 
dissolved in 50 µl cold buffer C and incubated 15 min on ice with frequently flicking of the 
tubes. A 5 min centrifugation at 17000g and 4°C followed before the supernatant containing 
the nuclear extracts was transferred to a new pre-cooled tube and placed at -80°C. Preparation 
of nuclear extracts was kindly performed by members of the group of Silke Appel. 
  
3.3.3 BCA protein Assay 
The exact amount of protein in the protein lysates prepared need to be determined. This was 
done by BCA protein assay. A 5 µl aliquot from each sample of protein lysate were thawed on 
ice. Standard was prepared from 1,5 mg/ml BSA with the following concentrations; 1,5 
mg/ml, 0,750 mg/ml, 0,375 mg/ml, 0,188 mg/ml, 0,094 mg/ml, 0,047 mg/ml, 0,023 mg/ml 
and a blank containing RIPA buffer. Unknown samples were diluted 1:5 in PBS and vortexed 
before 10 µl from each sample and standard were transferred to a 96 well plate in duplicates. 
Working Reagent (WR) was prepared by mixing 50 parts of BCATM Reagent A with 1 part of 
BCATM Reagent B (50:1), and 200 µl of the WR were added to each well. The plate was 
covered with adherent plastic and placed in a 37°C incubator. After 1hr, the plate was read at 
595 nm in a microplate reader where exact amount of proteins were defined. Results were 
analyzed by Soft Max Pro software. 
 30
  Methods 
3.3.4 SDS-PAGE 
 
Table 3.2: Gels used for SDS-PAGE 
 
Resolving gel 12%  Stacking gel 5%  
dH2O 3.4 ml dH2O 2.85 ml 
30% Acrylamide/Bis 4.0 ml 30%Acrylamide/Bis 0.85 ml 
1.5M Tris-HCl pH 8.8 2.5 ml 0.5M Tris-HCl pH 6.8 1.25 ml 
10% SDS 0.1 ml 10% SDS 50 µl 
10% APS 50 µl 10% APS 25 µl 
TEMED 10 µl TEMED 5 µl 
 
 
A 12 % resolving gel was prepared and pipetted into a MP3 glass cassette system. 
Isopropanol was layered on top of the resoling gel. After the gel had polymerized for 
approximately 30 min, the surface was rinsed with distilled water. Excess water was removed 
with filter paper and the stacking gel was added on top and a comb was inserted. After 
stacking gel had polymerized, gels were kept moist and cold until loading. 
 
According to BCA assay results, 20 µg of each protein sample were prepared in a volume of 
20 µl, diluted with RIPA buffer before 4µl 6x Lämmli buffer was added to each sample. For 
the nuclear extracts 15 µl of sample were used and 3 µl 6x Lämmli buffer was added to each 
sample. Samples were then denatured at 100°C for 5 min. Gel cassette was placed in a buffer 
chamber filled with 1x Running buffer. The comb was removed and wells were cleaned from 
unpolymerized acrylamide with running buffer using a syringe. Samples were loaded using 
pipette loading tips, and 6µl marker (Precision Plus Protein Standard, Kaleidoscope) was 
added to one well. To remaining empty wells, the appropriate amount of 6x Lämmli buffer 
were added. Gel electrophoresis was done at 150 V until the blue running front had left the 
gel, approximately 1 hour and 15 minutes. 
 
3.3.5 Western Blot 
Proteins were transferred from gel to membrane by Western blot. Wet Whatman filterpaper, 
gel, nitrocellulose membrane and filterpaper were placed in that order between fiber pads and 
placed in a gel cassette holder. Everything was kept moist by cold blotting buffer and a Bio-
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ice cooling unit was placed in the buffer tank with the gel cassettes. Proteins were transferred 
at 250 mA for 1h, while the blotting buffer was stirred to ensure equal temperature and ion 
distribution. After the transfer, the membrane was washed in 1x TBST (0.5%) and proteins 
were visualized by adding Ponceau S solution. The membrane was then cut to appropriate size 
and marked before it was incubated 1h in blocking buffer at RT with agitation. This was done 
to prevent unspecific binding of antibodies. Phospho specific primary antibodies were 
incubated overnight, 1:1000 in 5 % BSA in 1xTBST (0.1 %) at 4°C with agitation. Non-
phospho primary antibodies were incubated 1h, 1:1000 in 5 % milk in 1xTBST (0.5 %) at RT 
with agitation. Secondary antibodies were incubated 1h, 1:2000 in 5 % milk in 1xTBST (0.5 
%) at RT with agitation. Membrane was washed 4 x 5 min with 1xTBST (0.5 %) between 
incubation with primary and secondary antibody. After 1h incubation with secondary 
antibody, membrane was washed 4 x 5 min with 1xTBST (0.5 %) followed by 5 min with 
1xTBS. Proteins were then visualized by ImmunstarTM Western CTM Kit in a Chemi Doc 
machine and analyzed using Quantity One software. 
 
3.3.6 Stripping of the membrane 
Membranes were stripped to remove previously bound antibodies. This enabled detection of 
other antibodies toward other proteins of similar size. Stripping buffer without β-
Mercaptoethanol was prepared and warmed up to 60°C in a water bath. When buffer was 
warm, β-Mercaptoethanol was added under a fume hood. Membranes were then incubated in 
the stripping buffer for 30 minutes at 60°C with shaking. After incubation membranes were 
washed 5 x 5 minutes with 1xTBST (0.5%). 
 
3.4 Chemotaxis 
DC ability to migrate by chemotaxis towards chemokine CCL19 was tested. CCL19 binds to 
chemokine receptor CCR7 expressed on mature DC. A 96 transwellplate with 8 µm pore size 
was used. 235 µl RP10 + CCL19 (100 ng/ml) were added in the lower chamber, and 5x104 
DC in 80 µl RP10 were added to upper part before the plate was incubated for 5 h or 19 h in a 
humidified incubator at 37°C and 5% CO2. After incubation, cells that had migrated toward 
the lower chambers containing CCL19 were collected with the medium from the lower 
chambers. 235 µl cold PBS were added to each well to collect remaining cells before they 
were counted using Casy cell counter. In addition to analyzing the number of cells migrated 
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toward medium containing CCL19, number of cells migrated without CCL19 was analyzed. 
This was done by using pure RP10 medium not containing CCL19. 
 
3.5 Enzyme-linked immunosorbent assay (ELISA)  
ELISA MAXTM Set (Biolegend) was used to measure the cytokine secretion of the generated 
DC populations. Supernatants tested were collected and frozen down after the 24 h 
stimulation with bromelain or the cytokine cocktail.  
The ELISA was performed according to the protocol of the manufacturer. 
An IL-12p70 specific monoclonal capture antibody was coated on a 96-well plate. Next 
morning plate was washed 4 times with washing buffer. To block non-specific binding and to 
reduce background, plate was incubated with 1 X Assay Diluent for 1 h at RT with shaking. 
Plate was then washed 4 times with wash buffer. Samples and standard were then added in 
duplicates to the plate. Six two-fold serial dilutions of the 1000 pg/ml standard (recombinant 
human IL-12p70) were used. The plate was then incubated for 2 h at RT with shaking. IL-
12p70 present in samples will bind to capture antibody coated onto the plate. The wash 
procedure was then repeated, and the detection antibody coupled to biotin was added to the 
plate. The detection antibody will bind to the detected IL-12p70 in the samples during the 1 h 
incubation in RT with shaking. The wash procedure was repeated and an avidin horseradish 
peroxidase (av-HRP) was added to the plate and incubated 30 min in RT with shaking. 
Avidin-HRP amplifies the detection by the fact that several avidin molecules can bind to the 
biotin coupled to the detection antibody. The wash procedure was then repeated before a 
3,3’,5,5’-Tetramethylbenzidine (TMB) substrate was added and incubated in the dark for 15 
min. TMB is a visualizing reagent that produces a blue color in proportion to the amount of 
protein in the sample. This reaction was stopped by adding 1 M H2SO4 to the plate, the blue 
color then turns into yellow and the absorbance was read at 450 nm in a microplate reader. 
Results were analyzed by Soft Max Pro software. 
 
3.6 Mixed Lymphocyte Reaction (MLR) 
A MLR was performed to analyze the ability of the generated DC populations to stimulate T 
cell proliferation. The system used was allogeneic, where lymphocytes from another donor 
were used. These cells were collected as non-adherent cells (NAC) when monocytes where 
isolated from PBMC. 
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3.6.1 Preservation of NAC in cryotubes  
The cell suspension collected from the washing steps when monocytes were isolated was 
centrifuged for 5 min and 4°C at 400g, before the pellet was dissolved in 5 ml fetal bovine 
serum. Cryotubes enough for ±5x107 cells in each tube were prepared. 10% DMSO was 
added shortly before the cells were transferred to cryotubes, placed into Mr. Freeze and 
placed in a -80°C freezer. Mr. Freeze contains isopropanol and makes sure the cells are 
gradually frozen down to -80°C. 
 
3.6.2 Thawing of NAC 
One vial of NAC was taken out of the -80°C freezer and placed in a 37°C water bath. Right 
before it was completely thawed the vial was removed from the water bath and placed into the 
sterile bench. A small amount of prewarmed RP10 medium was added to the vial and the 
whole volume was then transferred to a 15 ml tube containing 9 ml pre-warmed RP10 
medium. The vial was washed with approx. 1 ml RP10 medium from the same tube to collect 
remaining cells. Cells were then centrifuged 5 min and RT at 400g. Supernatant were 
discarded, pellet was dissolved in 10 ml warm RP10 medium and centrifugation was repeated. 
After centrifugation cells were resuspended in 5 ml warm RP10 medium and transferred to a 
T25 flask and placed in humidified incubator 37°C and 5% CO2 over night. 
 
3.6.3 Labeling NAC with CFDA SE  
NAC were transferred from the T25 flask into a 15 ml tube. Cells were then centrifuged 5 min 
and RT at 400g before resuspended in 10 ml RP10 medium and counted. If cell aggregates 
were observed, the cells were passed through a cell filter, as it is important that the cell 
suspension consisted of single cells. The correct number of cells to be used was transferred 
into a new tube. Cells for labeling were then centrifuged and re-suspended in pre-warmed 
PBS/0.1% BSA at a concentration of 1x106cells/ml. CFDA SE was then added to the cell-
suspension, 1µl of 10 mM stock/ml followed by 10 min incubation at 37°C. Five volumes of 
ice-cold RP10 medium were added to the cells to quench the staining, before cells were 
incubated 5 min on ice. Cells were then centrifuged twice at 5 min and 4°C at 400g before 
being re-suspended in fresh RP10 medium at a concentration of 2x106 cells/ml RP10 medium.  
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3.6.4 Co-culturing DC with allogeneic lymphocytes 
DC were transferred to a 96 well cellculture plate in the concentration 5x104 DC in 100 µl 
RP10 medium. The next day 2x105 labeled allogeneic NAC in 100µl RP10 medium were 
added to the DC. In addition to the wells containing DC, the same amount of labeled NAC 
were also added to 3 empty wells used for compensation control for FITC, negative and 
positive control. The negative control is performed to be sure that the T cells do not 
proliferate without stimulation by allogeneic DC. As a positive control, one of the wells with 
labeled NAC was added PMA (25 ng/ml) and Ionomycin (1 µg/ml). Unlabelled NAC were 
also added to 3 wells for compensation controls. Wells with a total volume under 200 µl were 
added extra RP10 medium up to 200 µl. In addition, wells only containing DC were cultured. 
These were used to control that the DC populations did not contain too many lymphocytes, as 
these might show as proliferated cells when analyzed. Cell culture plate was then placed in 
humidified incubator at 37°C, 5% CO2 for 6 days for T cell proliferation before antibody 
staining and flow analysis were done. 
Staining with APC and PE mAb specific for CD4 and CD8 was performed as described 
previously in 3.2. 
 
3.7 Statistical analysis  
Statistical analyses were performed using Prism, results were analyzed using the Kruskal-
Wallis test. This is a non-parametric one-way ANOVA. This test state if there is a difference 
between the analyzed groups. A Dunns post-hoc test was then performed to analyze which 
groups that were different compared to each other. The difference between groups were 
considered significant if p<0.05. Significant differences between immature cells and cytokine 
DC are not shown in any of the figures, as these results are not relevant for this study.
  Results 
4 Results 
 
Immature DC were generated from monocytes by stimulation with GM-CSF and IL-4 for 6 
days. After the generation of immature DC, cells were matured for 24h. All cells still received 
IL-4 and GM-CSF. One cell population was matured with a cytokine cocktail containing 
TNF-α, IL-1β, IL-6 and PGE2, while others were stimulated with different concentrations of 
bromelain, to investigate the maturation effect bromelain has on immature DC. Some cells 
were kept immature by receiving only GM-CSF and IL-4. These are referred to as immature 
DC, while DC stimulated with the cytokine cocktail are referred to as cytokine DC. 
Bromelain concentrations investigated were 50µg/ml, 25µg/ml, 10µg/ml and 5µg/ml, and 
these are referred to by the concentration value. 
 
4.1  Cell viability and size 
4.1.1 DC viability is reduced by adding high concentrations of bromelain 
After 24h stimulation with different bromelain concentrations, the viability was examined 
with an automated CASY cell counter and compared to cytokine DC and immature DC. All 6 
independent experiments (n=4 with 5µg/ml bromelain) revealed the same trend. Figure 4.1 
shows that all cell populations stimulated with bromelain have a lower viability than DC 
stimulated with the cytokine cocktail. Cells that received the cytokine cocktail had the highest 
viability, while cells stimulated with 50µg/ml bromelain clearly had the lowest viability.  
The bromelain concentration showing the highest viability is 25µg/ml.  
 
4.1.2 Concentration dependent effect of bromelain on size of DC 
Cell size after 24h stimulation was also measured. Cells stimulated with 50µg/ml and 5µg/ml 
bromelain appeared more similar in size to immature cells. These were smaller in size than 
cells stimulated with the cytokine cocktail. Stimulation with 25µg/ml and 10µg/ml bromelain 
resulted in DC with similar size to cytokine DC (figure 4.2). 
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Figure 4.1: DC stimulated with bromelain have lower viability than DC stimulated with the cytokine 
cocktail and immature DC. Monocyte derived DC were incubated for 24h with different concentrations of 
bromelain and their viability was compared to DC stimulated with a cytokine cocktail (TNF-α, IL-1β, IL-6 and 
PGE2) and immature DC. Viability was determined with an automated CASY cell counter. Six independent 
experiments are shown (n=4 for 5µg/ml bromelain) and median is indicated by a bar. Cytokine DC are DC 
matured with the cytokine cocktail. The highest concentration of bromelain (50µg/ml) showed an apparent lower 
viability compared to the other populations, and all DC receiving bromelain had lower viability than cytokine 
DC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: DC stimulated with 25µg/ml and 10µg/ml bromelain have similar size to DC stimulated with 
the cytokine cocktail, whereas DC stimulated with higher and lower concentrations of bromelain are 
smaller in size. Monocyte derived DC were incubated for 24h with different concentrations of bromelain and 
their sizes were compared to DC stimulated with a cytokine cocktail (TNF-α, IL-1β, IL-6 and PGE2 and 
immature DC. Cell size was measured with an automated CASY cell counter. Six independent experiments are 
shown (n=4 for 5µg/ml bromelain) and median is indicated by a bar. Cytokine DC are DC stimulated with the 
cytokine cocktail. DC stimulated with 50µg/ml and 5µg/ml bromelain are smaller in size and thus more alike 
immature DC 
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4.2 Phenotype analyses of generated DC 
The phenotype of the different DC populations was analyzed by flow cytometry and 2x104 
cells were analyzed. In order to exclude lymphocytes and cell debris from the analysis, DC 
were gated according to size and granularity. Figure 4.3 shows the gating strategy on a 
representative plot using FlowJo software. 
 
 
                                   
 
 
 
 
 
 
 
Figure 4.3: Generated DC were gated according to size and granularity. Forward scatter channel (FSC) 
indicates size and side scatter channel (SSC) indicates the granularity of the analyzed cells. When DC are gated 
after these conditions, lymphocytes and debris are excluded from the analysis, and only DC appear in the 
calculations. 
 
 
4.2.1 DC markers indicate successful generation of DC 
Staining with antibodies toward surface markers can give an indication of the phenotype of 
the generated cell populations. I could confirm by flow cytometry that the generation of DC 
from monocytes had been successful. As expected the DC generated had low expression of 
CD14 (A) in addition to high CD1a (B) expression as shown in figure 4.4. This indicates that 
the generated cells are monocyte derived DC.  
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Figure 4.4: DC stimulated with bromelain express DC marker CD1a, and they do not express CD14. 
Monocyte derived DC were incubated for 24h with different concentrations of bromelain and compared to DC 
stimulated with a cytokine cocktail (TNF-α, IL-1β, IL-6 and PGE2) and immature DC. Six independent 
experiments are shown (n=4 for 5µg/ml bromelain) and median is indicated by a bar. Cytokine DC are DC 
matured with the cytokine cocktail. Percentage of cells expressing CD14 and CD1a were determined by flow 
cytometry. Results reveal that all cell populations express high amounts of DC markers CD1a (A), in addition to 
almost no expression of the macrophage/monocyte marker CD14 (B). This indicates that generation of DC from 
monocytes has been successful.  
 
 
4.2.2 Concentration dependent upregulation of maturation markers 
following treatment with bromelain 
Surface markers indicating maturation for DC were examined by flow cytometry. Matured 
DC should have higher expression of HLA-DR and CD83 as well as lower expression of 
CD91 when compared to immature DC. The expression of these surface markers on 
bromelain stimulated DC therefore indicates the maturation effect bromelain has on immature 
DC. Figure 4.5 shows the expression of these surface markers in 6 independent experiments. 
Cytokine DC had high expression of HLA-DR (A) and CD83 (B), while immature DC 
showed lower expressions of these surface markers. DC stimulated with bromelain had 
somewhat lower expression of HLA-DR and CD83 compared to cytokine DC. CD91 
expression was high on the immature DC population, while lower on the DC stimulated with 
the cytokine cocktail. Bromelain stimulated DC showed an even more pronounced 
downregulation of this marker, and a significant reduction was detected between immature 
DC and DC stimulated with 50µg/ml bromelain. These results indicate a somewhat less 
mature phenotype for bromelain treated DC compared to DC stimulated with the cytokine 
cocktail.  
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Figure 4.5: Concentration dependent upregulation of maturation markers following treatment with 
bromelain Monocyte derived DC were incubated for 24h with different concentrations of bromelain and 
compared to DC stimulated with a cytokine cocktail (TNF-α, IL-1β, IL-6 and PGE2) and immature DC. Six 
independent experiments are shown (n=4 for 5µg/ml bromelain) and median is indicated. Cytokine DC are DC 
matured with a cytokine cocktail. Percentage of cells expressing HLA-DR, CD83 and CD91 were determined by 
flow cytometry. Cytokine DC show high expression of  HLA-DR (A) and CD83 (B), while immature DC show 
low expression of these markers. Bromelain stimulated DC expressed less for these maturation markers 
compared to cytokine DC, although an upregulation was detected when bromelain stimulated cells were 
compared to immature cells. Percentage of CD91 positive DC was lower for all populations compared to their 
origin, immature DC. However, higher concentrations of bromelain showed a greater decrease than the other cell 
populations, and 50µg/ml bromelain DC had a significant downregulation of CD91 compared to immature DC 
(C). Kruskal-Wallis and Dunns post-hoc test were used for statistical analyses, and * indicates p< 0.01. 
 
 
4.2.3 Co-stimulatory molecules are expressed on bromelain stimulated 
DC 
Proliferation and differentiation of naive T cells require an extra signal in addition to the 
antigen induced signal. The second signal is provided by co-stimulatory molecules present on 
DC and their ligands on T cells. CD40, CD80 and CD86 are all co-stimulatory molecules on 
DC. The expression of these surface molecules are expected to be upregulated on matured DC 
compared to immature DC. Results from these markers are shown in figure 4.6. In (A) the 
expression of CD80 is vizualized. The DC population with the highest percentage of positive 
cells for this marker is the one stimulated with 50µg/ml bromelain. The other concentrations 
of bromelain stimulated cells had CD80 expressions more like immature DC. CD86 is clearly 
upregulated DC treated with bromelain when compared to immature cells, although cytokine 
DC have an even higher expression (B). All DC populations show high percentages of cells 
positive for CD40 (C). While percentage of positive cells shows the number of cells 
expressing the molecule, the median fluorescence intensity (MFI) indicates the quantity of the 
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molecule on each cell. MFI measured for CD40 reveals that treatment with bromelain results 
in higher quantity of CD40 on the cells surface (D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Bromelain stimulated DC express co-stimulatory molecules, although less than cytokine DC. 
Monocyte derived DC were incubated for 24h with different concentrations of bromelain and compared to DC 
stimulated with a cytokine cocktail (TNF-α, IL-1β, IL-6 and PGE2) and immature DC. Six independent 
experiments are shown (n=4 for 5µg/ml bromelain) and median is indicated by a bar. Cytokine DC are DC 
matured with the cytokine cocktail. Percentage of cells expressing CD80, CD86 and CD40 and the MFI  were 
determined by flow cytometry. High concentrations of bromelain stimulation lead to upregulation of CD80, 
lower concentrations show no upregulation compared to immature cells expression (A). CD86 is clearly 
upregulated on bromelain DC compared to the expression on immature cells (B). All cell populations generated 
show high percentages of cells positive for CD40 (C), and MFI measured indicate higher amount of CD40 on 
cells stimulated with bromelain (D). 
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4.2.4 Migration markers show low CCR7 and high CD38 expression on 
bromelain stimulated DC 
In addition to DC and maturation and co-stimulatory markers, surface molecules known to 
affect migration of DC were analyzed. The ability to migrate to the lymph nodes after 
encounter with an antigen is important for immune responses since DC need to encounter 
with naïve T cells, and these have their residence in the lymph nodes. CCR7 is a chemokine 
receptor that drives the DC to the lymph nodes where its ligands, CCL19 and CCL21 is 
expressed at high concentrations. Another molecule shown to affect the migration of DC is 
CD38. CD38 is a 45 kD multifunctional type II transmembrane glycoprotein, and has shown 
to function as an ectoenzyme, regulating immune cells (44). Its expression is upregulated on 
activated cells and therefore proposed to be a marker for cell activation (45), but not much is 
known concerning its functions on DC. Figure 4.7 shows that DC stimulated with the 
cytokine cocktail had upregulated expression of the chemokine receptor CCR7, while only 
few DC stimulated with bromelain and immature DC expressed this molecule (A). CD38 
expression was clearly upregulated on all populations treated with bromelain, whereas CD38 
expression on cytokine DC was downregulated. Cell populations stimulated with 50µg/ml and 
25µg/ml bromelain had significantly higher percentage positive cells compared to cytokine 
DC (B).  
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Figure 4.7: Bromelain stimulated DC have low CCR7 and upregulated CD38 expression. Monocyte derived 
DC were incubated for 24h with different concentrations of bromelain and compared to DC stimulated with a 
cytokine cocktail (TNF-α, IL-1β, IL-6 and PGE2) and immature DC. Six independent experiments are shown 
(n=4 for 5µg/ml bromelain) and median is indicated by a bar. Cytokine DC are DC matured with the cytokine 
cocktail. Percentage of cells expressing CCR7 and CD38 were determined by flow cytometry. Bromelain treated 
and immature DC show low percentages of cells positive for CCR7 compared to cytokine DC(A). CD38 
expression on bromelain stimulated DC was clearly increased compared to immature cells, Cells stimulated with 
50µg/ml and 25µg/ml bromelain had significantly higher CD38 expression compared to cytokine DC. These 
showed the opposite result, where CD38 was downregulated (B). Kruskal-Wallis and Dunns post-hoc test were 
used for statistical analyses, and * indicates p< 0.001. 
 
 
4.3 Phosphorylation pattern of cellular proteins 
Phosphorylated and non-phosphorylated MAP kinase proteins and Akt/PKB from protein 
lysates were examined by Western blotting. The results were analyzed using ChemiDoc 
software. The band intensity for cytokine DC was set as 100% and the band intensities of the 
other cell populations were compared relative to this. Ratio between phosphorylated and non-
phosphorylated proteins was calculated by dividing the value for the phosphorylated band by 
the value obtained for the total amount of the protein. Six independent experiments (n= 4 for 
5µg/ml bromelain) were analyzed. 
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4.3.1 DC stimulated with bromelain have higher values of phosphorylated 
ERK and p38 and less phosphorylated JNK compared to DC 
stimulated with the cytokine cocktail 
A representative Western blot and ratio between phosphorylated ERK (p-ERK) and total ERK 
are illustrated in figure 4.8. These clearly indicate that cytokine DC had lower amounts of 
phosphorylated ERK. In addition to DC stimulated with bromelain, immature DC also 
showed high values of p-ERK. 
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Figure 4.8: Bromelain stimulated DC show more phosphorylated ERK than cytokine DC. Monocyte 
derived DC were incubated for 24h with different concentrations of bromelain and compared to DC stimulated 
with a cytokine cocktail (TNF-α, IL-1β, IL-6 and PGE2) and immature DC. A representative Western blot of 
phosphorylated ERK (p-ERK) and total ERK is shown (A), where a 12% resolving gel was used. The band 
density for cytokine DC was set as 100%. The ratios between p-ERK and ERK from all 6 independent 
experiments are shown in B. Median is indicated by a bar. All experiments showed similar results, indicating 
that cytokine DC had clearly lower amounts of p-ERK than immature and bromelain stimulated DC. 
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Results from analyses of phosphorylated p38 (p-p38) and total p38 on DC stimulated with 
bromelain are shown in figure 4.9. When compared to DC stimulated with the cytokine 
cocktail, the bromelain treated cells had more phosphorylated p38, although not clearly higher 
values. DC populations expressing the highest phosphorylation level of p38 is 25µg/ml and 
10ml/µg bromelain. 
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Figure 4.9: Bromelain stimulated DC show more phosphorylated p38 than Cytokine DC. Monocyte derived 
DC were incubated for 24h with different concentrations of bromelain and compared to DC stimulated with a 
cytokine cocktail (TNF-α, IL-1β, IL-6 and PGE2) and immature DC. A representative Western Blot of 
phosphorylated p38 (p-p38) and total p38 is shown (A), where a 12% resolving gel was used. The band density 
for cytokine DC was set as 100%. The ratios between p-p38 band and p38 band from all 6 independent 
experiments are shown in B. Median is indicated by a bar. 25µg/ml and 10µg/ml bromelain had the highest 
values of phosphorylated p38, while 50µg/ml and 5µg/ml had a lower median value, closer to the median value 
for cytokine DC 
 
 
 
JNK phosphorylation was also examined. As shown in figure 4.10, bromelain stimulated DC 
had less JNK phosphorylation than cytokine DC.  This was the case for all concentrations of 
bromelain treated cells, and immature DC had even lower phosphorylation values. Figure 4.10 
(A) shows a representative Western blot. As the figure indicates, the level of phosphorylated 
JNK is very low for immature DC and for the lowest concentrations of bromelain stimulated 
cells. 
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Figure 4.10: Bromelain stimulated DC show less phosphorylated JNK than Cytokine DC. Monocyte derived 
DC were incubated for 24h with different concentrations of bromelain and compared to DC stimulated with a 
cytokine cocktail (TNF-α, IL-1β, IL-6 and PGE2) and immature DC. A representative Western blot of 
phosphorylated JNK (p-JNK) and total JNK is shown (A), where a 12% resolving gel was used. The band 
density for cytokine DC was set as 100%. The ratios between p-JNK bands and JNK bands from all 6 
independent experiments are shown in B. Median is indicated by a bar. Immature DC, in addition to all 
concentrations of bromelain stimulated DC showed considerably lower values of p-JNK than DC stimulated with 
the cytokine cocktail. 
 
 
4.3.2 Three experiments with similar results indicate that cytokine DC 
had less amount of p-AKT compared to bromelain treated cells. 
Figure 4.11 (A) shows a representative Western blot of phosphorylated AKT (p-AKT) and 
total AKT, and (B) shows the ratio between p-AKT and AKT for 5 independent experiments. 
One of the six experiments had no phosphorylated AKT. Out of the five experiments with 
detectable p-AKT, one showed very high values for the bromelain stimulated DC while 
another had lower values for the same DC populations. The three experiments with similar 
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results indicate that cytokine DC had less amount of p-AKT compared to bromelain treated 
cells. 
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Figure 4.11: Bromelain stimulated DC show more phosphorylated AKT than Cytokine DC. Monocyte 
derived DC were incubated for 24 h with different concentrations of bromelain and compared to DC stimulated 
with a cytokine cocktail (TNF-α, IL-1β, IL-6 and PGE2) and immature DC. A representative Western blot of p-
AKT and total AKT is shown (A), where A 12% resolving gel was used. The band density for cytokine DC was 
set as 100%. The ratio between p-AKT band and AKT band from all 5 independent experiments is shown in B. 
Median is indicated by a bar. Out of 6 experiments, 3 had similar results, where there was detected more p-AKT 
in bromelain stimulated DC compared to cytokine DC. One experiment had very high values of p-AKT in the 
bromelain treated DC populations, another showed lower p-AKT values for these DC populations, while the last 
experiment had no measurable p-AKT levels. 
 
 
4.4 Bromelain stimulated DC have upregulated nuclear RelB 
expression compared to immature DC, but they do not 
express as much nuclear RelB as cytokine DC 
 
Nuclear extracts were examined and analyzed for RelB expression by Western blot. RelB is a 
subunit of the NF-κB transcription factor family and studies implicate RelB to be an 
important regulator in the differentiation of DC (46). To make sure all wells had equal 
loading, the blot was reprobed with an antibody against TATA binding protein (TBP). 4 
independent experiments (n=3 for immature DC and 10µg/ml bromelain, and n=0 for 5µg/ml 
bromelain) are included in the analysis of nuclear RelB. Amounts of nuclear RelB present in 
the different DC populations are shown in figure 4.12. 
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Figure 4.12: Bromelain stimulated DC have less nuclear RelB expression compared to Cytokine DC. 
Monocyte derived DC were incubated for 24h with different concentrations of bromelain and compared to DC 
stimulated with a cytokine cocktail (TNF-α, IL-1β, IL-6 and PGE2) and immature DC. A representative Western 
blot of nuclear RelB expression is shown (A), where a 12% resolving gel was used. The band density for 
cytokine DC was set as 100%.  Nuclear RelB expression for 4 independent experiments (n=3 for immature and 
10µg/ml bromelain and n=0 for 5µg/ml bromelain) is shown in B, median is indicated by a bar. Compared to DC 
stimulated with the cytokine cocktail bromelain treated DC had less nuclear RelB. However they expressed more 
nuclear RelB than immature DC. 
 
 
4.5 DC stimulated with bromelain produce more IL-12p70 than 
cytokine DC 
 
After 24h of stimulation with bromelain and the cytokine cocktail, respectively, supernatants 
from all different DC populations were collected. The amount of the active form of IL-12, IL-
12p70 produced by the different DC populations was analyzed by ELISA. The minimum 
detectable concentration of IL-12p70 was 4pg/ml. Although overall low amounts of IL-12p70 
were produced, the result revealed that in 4 out of 5 experiments, bromelain stimulated DC 
produced more IL-12p70 than DC matured with the cytokine cocktail. Immature DC did not 
produce measurable amounts of IL-12. This was also the case for DC stimulated with only 
5µg/ml bromelain; here in 3 of 4 experiments no secretion of IL-12 could be detected. DC 
stimulated with 25µg/ml bromelain had a clearly higher production of IL-12p70 compared to 
the other DC populations.  
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Figure 4.13: Bromelain stimulated DC produce more IL-12p70 than DC matured with cytokine cocktail. 
Monocyte derived DC were incubated for 24h with different concentrations of bromelain and compared to DC 
stimulated with a cytokine cocktail (TNF-α, IL-1β, IL-6 and PGE2) and immature DC. Supernatants were 
collected after 24h stimulation and stored at -20°C. DC stimulated with bromelain produced more IL-12p70 than 
cytokine DC in four out of 5 experiments. DC stimulated with 25µg/ml bromelain showed a higher production 
compared to the other DC populations. Immature DC did not produce measurable amounts of IL-12p70. DC 
stimulated with 5µg/ml bromelain only had one value that could be measured while the others were under the 
limit (4pg/ml) for detection of IL-12p70. Median is indicated by a bar in the figure. 
 
 
4.6 Chemotaxis 
 
The migratory capacity of the generated DC populations was analyzed in a chemotaxis assay 
towards CCL19. Mature DC express CCR7 which is the receptor for CCL19. Because of this, 
mature DC are expected to migrate toward a gradient containing CCL19. Migration was 
performed for 5 hours and 19 hours. To control random migration, DC migrating without a 
gradient of CCL19 were also examined. Figure 4.14 shows two experiments performed with 
only 5 h incubation (A), and two experiments performed with 19 h incubation (B). The 4 
independent experiments are shown separately in individual figures due to large variations. 
Overall, few DC migrated, however, the 19 h incubations indicate somewhat more migrated 
cells than 5 h incubations. The number of DC migrating toward medium without CCL19 is 
approximately the same as DC migrating toward CCL19, and no clear difference was 
discovered between the different DC populations except for less migrated immature DC after 
19 h incubation (B).   
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Figure 4.14: Similar migratory capacity of the different DC populations. Monocyte derived DC were 
incubated for 24h with different concentrations of bromelain, a cytokine cocktail (TNF-α, IL-1β, IL-6 and 
PGE2), or kept immature. After ended incubation, cells were harvested and 5x104 DC were transferred to the 
upper chambers on a 96 transwellplate with 8 µm pore size. RP10 medium with and without CCL19 was added 
to the lower chambers. After 5 h or 19 h migrated DC were collected from the lower chambers and counted with 
an automated CASY cell counter 
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4.7 MLR 
 
After 24 h of stimulation with the cytokine cocktail or bromelain, respectively, 5x104 DC 
from each cell population were transferred to a 96 well plate. The next day 2x105 NAC 
labeled with CFDA SE were added to each well. Cells convert CFDA SE into CFSE that can 
be detected. For each cell division, the fluorescence intensity of CFSE is decreased by half. In 
this way we can detect proliferating cells. DC and NAC were co-cultured for 6 days before 
the cells were harvested and their proliferation potential was analyzed by flow cytometry. 
Figure 4.15 shows how the proliferated lymphocytes look in a light microscope. 
 
Cytokine DC 10µg/ml Bromelain 
 
 
 
 
 
 
 
 
 
Figure 4.15: Stimulated DC induce proliferation of lymphocytes. Picture taken before cells were harvested 
after 6 days co-culture of 2x105 allogeneic NAC and 5x104 DC from each cell population. Distinct clustering of 
proliferated lymphocytes could be visualized in the light microscope (40x), here represented by NAC co-cultured 
with cytokine DC and DC stimulated with 10µg/ml bromelain, respectively. Both DC populations induce 
proliferation of allogeneic lymphocytes. 
 
 
 
4.7.1 DC stimulated with bromelain show similar abilities to activate 
allogeneic lymphocytes as cytokine DC 
Lymphocytes were gated according to size and granularity, this is shown in the upper panel of 
figure 4.16 (A) together with a control group containing CFSE labeled NAC in the lower 
panel. This control consists of only NAC without additional DC. Its function is to eliminate 
suspicion of lymphocyte proliferation induced by DC present in the NAC population, as 
proliferated cells would be visualized by reduced amount of CFSE in the histogram. Only one 
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MLR was performed, and these results are shown. Numbers of proliferated lymphocytes are 
shown in figure 4.16 (B). All different DC populations have the ability to stimulate 
lymphocyte proliferation, even immature DC. This experiment indicates that DC stimulated 
with bromelain have the same, if not an enhanced ability to activate allogeneic lymphocyte 
proliferation compared to DC stimulated with the cytokine cocktail. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: Bromelain stimulated DC have the ability to activate proliferation of lymphocytes. Monocyte 
derived DC were incubated for 24h with different concentrations of bromelain and a cytokine cocktail (TNF-α, 
IL-1β, IL-6 and PGE2), in addition one population of DC was kept immature. DC were then incubated with 
NAC/T-cells for 6 days before harvested and analyzed by flow cytometry. Figure A upper panel shows how 
CD4+ and CD8+ T lymphocytes are gated according to size (FSC) and granularity (SSC), while lower panel 
shows the negative control containing only labeled NAC. Figure B shows the percent proliferated lymphocytes, 
stimulated by the different DC populations. Numbers of proliferated cells are represented on the Y axis and the 
amounts of CFSE detected are shown on the X axis. The different DC populations show approximately the same 
ability to induce proliferation of allogeneic lymphocytes. 
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Amount of CD4+ and CD8+ T lymphocytes was also detected separately by flow cytometry in 
order to see which subset of T cells that proliferated. Proliferated lymphocytes were stained 
with CD4 and C8 antibodies and number of cells belonging to each cell population was 
determined. Figure 4.17 show the quantity of proliferated CD4+ T lymphocytes stimulated by 
the different DC populations. Bromelain stimulated DC, with the exception of 50µg/ml, 
induces more CD4+ T cell proliferation than cells stimulated with the cytokine cocktail. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17: Bromelain stimulated DC have the ability to activate proliferation of CD4+ T-lymphocytes. 
Monocyte derived DC were incubated for 24h with different concentrations of bromelain and a cytokine cocktail 
(TNF-α, IL-1β, IL-6 and PGE2), in addition one population of DC was kept immature. DC were then incubated 
with NAC/T-cells for 6 days before harvested and analyzed by flow cytometry. Figure A upper panel shows how 
CD4+ and CD8+ T lymphocytes are gated according to size (FSC) and granularity (SSC), while lower panel 
shows the negative control containing only labeled NAC. Figure B shows the percent proliferated CD4+ T-
lymphocytes stimulated by the different DC populations. Numbers of proliferated cells are represented on the Y 
axis and the amounts of CFSE detected are shown on the X axis. Bromelain stimulated DC seem to be more 
potent in inducing proliferation of CD4+ T-lymphocytes. 
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Figure 4.18 show the quantity of proliferated CD8+ T lymphocytes stimulated by the different 
DC populations. The different DC populations generated show approximately the same 
potential for inducing CD8+ T lymphocytes proliferation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18: Bromelain stimulated DC have the ability to activate proliferation of CD8+ T-lymphocytes. 
Monocyte derived DC were incubated for 24h with different concentrations of bromelain and a cytokine cocktail 
(TNF-α, IL-1β, IL-6 and PGE2), in addition one population of DC was kept immature. DC were then incubated 
with NAC/T-cells for 6 days before harvested and analyzed by flow cytometry. Figure A upper panel shows how 
CD4+ and CD8+ T lymphocytes are gated according to size (FSC) and granularity (SSC), while lower panel 
shows the negative control containing only labeled NAC. Figure B shows the percent proliferated CD4+ T-
lymphocytes stimulated by the different DC populations. Numbers of proliferated cells are represented on the Y 
axis and the amounts of CFSE detected are shown on the X axis. 
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Several clinical applications have shown that the maturation status of DC have an important 
role in initiating and directing immune responses (47). The discovery of new reagents for the 
promotion of DC maturation is therefore of interest for many scientists. The purpose behind 
this study was to see the effect of bromelain on DC maturation. Immature DC were generated 
from monocytes isolated from human PBMC. They were stimulated for 24 hours with various 
concentrations of bromelain, before being analyzed and compared to DC stimulated with the 
“gold standard”, a cytokine cocktail consisting of TNF-α, IL-1β, IL-6 and PGE2. Since the 
influence of bromelain on DC has not been investigated earlier, several different outcomes 
could be expected.  
 
Previous experiments performed with bromelain on glioma cells had shown that bromelain 
did not produce any cellular toxicity (42). This was confirmed also during my experiments. 
However, cells treated with the highest concentration of bromelain, 50µg/ml, showed the 
lowest viability in all 6 independent experiments. In one or another way, high concentration 
of bromelain slightly affects DC viability, even though glioma cells were not notably affected 
by this. 
 
After 24 h of stimulation with different concentrations of bromelain, the phenotype of the 
different cell populations was analyzed by flow cytometry. These results revealed that 
treatment with bromelain on immature cells did induce a signal that shifted the immature DC 
towards a mature DC phenotype. Although they clearly had been altered, the results indicated 
that they had a less mature phenotype than DC stimulated with the cytokine cocktail. 
Analyses of phosphorylated MAP kinase proteins and AKT in bromelain treated DC imply a 
phosphorylation pattern more similar to immature DC than cytokine DC. Nuclear RelB 
expression was lower than in cytokine DC, however it was still higher than for immature 
cells. Bromelain stimulated DC show a little less migratory capacity compared to cytokine 
DC, but the results show substantial variation and any clear conclusion is difficult to reach 
before more experiments have been performed. The mixed lymphocyte reaction performed 
indicated that bromelain DC and cytokine DC had approximately the same potential for 
activating allogeneic lymphocytes. Cell culture supernatants were analyzed for IL-12p70 
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content to investigate the different DC population’s cytokine secretion. Bromelain treated DC 
revealed a clearly higher IL-12p70 production when compared to cytokine DC. 
The results indicate a clear concentration dependent effect caused by bromelain. DC treated 
with the lowest concentration, 5µg/ml bromelain displayed few signs indicating any cell 
maturation. These cells had low upregulation of co-stimulatory and MHC class II molecules 
as well as low IL-12 secretion. They also showed the lowest level of nuclear RelB. In the 
discussion this concentration (5µg/ml) of bromelain will not be mentioned in context with the 
other concentrations as a maturation inducing stimuli.  
 
The bromelain concentration that showed the most promising results was 25µg/ml bromelain. 
Nuclear RelB levels were most pronounced in cells stimulated with 25µg/ml bromelain, 
compared to the other concentrations. The most exciting result was the amount of secreted IL-
12p70, where bromelain stimulated DC showed higher production than cytokine DC, and also 
here, 25µg/ml showed the best result. Studies have revealed that lack of IL-12p70 production 
is one of the most important deficiencies of the cytokine cocktail (48). Immune responses 
toward tumors demand strong CTL activation to be able to fight the tumor cells. IL-12 has a 
pivotal role concerning CTL activation, by stimulating Th1 cells that help inducing even 
stronger CTL responses by activating these killer cells (18). As revealed by recent studies, the 
use of PGE2 in the cytokine cocktail is responsible for inhibiting IL-12 production in DC (49). 
However, PGE2 does possess other good qualities, and therefore it is still used in the “gold 
standard” cytokine cocktail. One of the positive effects caused by PGE2 is the induction of 
survivin expression in DC. This has shown to increase DC viability by conferring protection 
from apoptosis (50). In addition studies have shown that PGE2 stimulation of DC is central 
concerning their CCR7 surface expression (51). 
  
The DC homing receptor CCR7 has been shown to be important for the ability of DC to 
migrate toward lymph nodes where they interact with lymphocytes and initiate immune 
responses (52). CCR7 was not notably upregulated on any DC population stimulated with 
different concentrations of bromelain, but these cells showed the same level of CCR7 
expression as immature cells. Since the cytokine cocktail used contains PGE2, it was expected 
that DC stimulated with the cocktail expressed higher levels CCR7. CCL19 and CCL21, 
which are ligands for CCR7, are expressed in lymphatic vessels and in the T cell areas of the 
lymph nodes. This chemokine gradient are supposed to affect the DC, and make them migrate 
to these areas where they meet and interact with T cells (51). However, it was discovered that 
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the migratory ability of the generated DC did not seem to be affected by the gradient of 
CCL19. Nearly the same number of cells migrated without this chemokine gradient. This was 
noticed since we analyzed migration toward pure medium as a control to detect any unspecific 
migration. Migration of DC is a complex chain of events, and obviously other factors also 
control and affect the movement of these cells. In the migration assay we used RP10 medium. 
Included in this medium is FBS that contains several unknown factors. Since these factors are 
unidentified it might for all we know also include CCL19, and thereby the produced gradient 
is eradicated. One possible solution is to use serum free medium like X-VIVO for future 
migration assays. 
Another surface receptor on DC, CD38, has also been shown to contribute to migration of DC 
(53). CD38 is known to activate signals of immune cells, and induce their cytokine secretion. 
Some years ago it was shown that inhibition of CD38 expression reduced CCL21 driven 
chemotaxis in monocyte derived DC (53). CD38 is involved in activation processes of 
different cell types, therefore the expression of CD38 during differentiation of human 
monocytes into immature and mature DC was analyzed by Fedele and co-workers (45). In this 
study it was shown that human monocytes are CD38+, and that the expression is lost during 
the development into immature DC, which are CD38-. When these immature cells were 
stimulated with LPS for 48 hours, a rapid upregulation of CD38 was induced, but the effect of 
the cytokine cocktail was not investigated (45). Results from my experiments show that DC 
treated with the cytokine cocktail had low expression of CD38. Immature DC had more CD38 
expressed than cytokine DC, while bromelain stimulated DC expressed even higher 
percentages of cells positive for CD38 (shown in figure 4.7 B). These results were obviously 
concentration dependent, where the highest concentrations of bromelain had the highest 
percentage of positive cells, and the other concentrations follow with reduced values of 
CD38+ cells. Bromelain induces CD38 expression on DC, while the cytokine cocktail 
restrains this. It was recently reported that INFα induces upregulation of CD38 on DC when 
used as an adjuvant in combination with the cytokine cocktail (54).  
 
CD91 is a receptor for heat shock proteins and involved in endocytosis in human cells (31). 
Since immature DC have the ability to endocytose while mature DC have lost this 
characteristic, it was expected that immature DC express more CD91 than mature cells. 
Figure 4.5 C shows that this is the case in my experiments. Immature DC have the highest 
percentage of cells positive for CD91, Cytokine DC have clearly lower values while 
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bromelain treated DC express even less CD91. This indicates that bromelain treated DC have 
poorer ability to endocytose, and therefore their action is possibly shifted toward performing 
tasks of mature DC such as antigen presentation instead. 
 
Another indicator of DC maturation is the expression of nuclear RelB which is a member of 
the NF-κB transcription factor family. Mouse models and human studies implicate RelB to be 
an important regulator during the differentiation and maturation of DC (46, 55) RelB 
knockout mice show reduced amounts of DC, while in human cells expression is correlated 
with activation of DC, and RelB mRNA was only detected in the later stages of DC 
differentiation. (46, 55). Bromelain stimulated DC expressed various amounts of nuclear 
RelB, dependent on the concentration of bromelain used. Cells stimulated with 25µg/ml 
bromelain showed more nuclear RelB than cells stimulated with the other concentrations of 
bromelain. This is in coherence with the rest of my results, indicating 25µg/ml to be the 
bromelain concentration leading to the most matured DC population. Only 4 of my 6 
experiments of nuclear RelB expression could be included in the results. When the TBP 
control was analyzed, two of the blots showed uneven loading of proteins, and therefore could 
not be used. Since a BCA assay was not performed on nuclear extracts due to incompatibility 
of EGTA with the assay, the exact amounts of proteins in each sample was not determined. 
Even though we always used 5x105 cells to prepare nuclear extracts, this is not as accurate as 
a BCA assay. 
 
When phosphorylation of MAP kinase proteins and AKT from my experiments was 
examined, the results revealed an unexpected pattern. DC stimulated with the cytokine 
cocktail had lower amounts of phosphorylated proteins compared to immature and bromelain 
treated DC. Previous analyses has shown that MAP kinase proteins activity are affected by 
maturation and activation of DC (19). For that reason we expected to see a variation among 
phosphorylated MAP kinase proteins in the different DC populations, due to different 
stimulations and thereby altered maturation status and signaling by the cells. Since DC 
stimulated with the cytokine cocktail are known to be activated, the expected result was at 
least that these DC would have high amounts of the phosphorylated proteins. Since other 
results confirm that cytokine DC have been activated and matured, it leads us to the 
assumption that stimulation for 24 hours may be to extensive to detect high phosphorylation 
values. Some proteins have their highest phosphorylation values probably a short time after 
stimulation. When I harvested cells and prepared protein lysates after 24 hours, 
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phosphorylation of MAPK proteins for the cytokine DC population probably already had 
passed the maximum value of phosphorylated proteins. This results in lower detected levels of 
phosphorylated proteins since the phosphorylation are removed after activation of the kinases 
and their activation of downstream proteins. If assuming this to be a possible reason for low 
values for cytokine DC, it is also plausible that phosphorylation values for bromelain 
stimulated DC also is not optimal. Therefore it is desirable to perform phospho protein 
analyses after shorter stimulation periods. The stimulation period was decided to be 24 h in 
my experiments since phenotypic analyses by flow cytometry, as well as cytokine secretion 
by ELISA are not measurable after shorter stimulation periods. The DC need some time to 
change the expression of surface molecules, in addition to translate and secrete cytokines.  
 
In view of the fact that only one MLR was performed, more experiments are required before 
anything can be stated conclusively. However, these preliminary results indicate that DC 
stimulated with bromelain do hold a potential for stimulating lymphocytes and initiating 
immune responses. We did not isolate CD3+ cells from NAC for this experiment, therefore it 
is expected that proliferated B cells also are present in the number of proliferated lymphocytes 
measured. However, the amount of CD4+ and CD8+ T lymphocytes that had proliferated were 
accurately quantified since these cells were detected by CD4 and CD8 specific antibodies. 
The DC populations used in these types of experiments could be contaminated by some 
lymphocytes not washed away when monocytes were isolated from PBMC. This problem 
could be reduced if CD14+ cells were isolated from PBMC, and cultured. A purer DC 
population will then be generated, and the possible effect of the lymphocytes present in the 
culture can be eliminated. It is likely that I had some lymphocytes in my DC populations, 
however, my results do show differences in the number of proliferated cells stimulated by the 
various DC populations. This indicates that the proliferation of the lymphocytes is due to 
different stimulations performed by the DC populations, or else we would expect similar 
proliferation in all populations.   
 
5.1 Conclusion 
 
Although the results show that bromelain stimulated DC are less mature than cytokine DC, 
demonstrated by phenotype analyses, nuclear RelB expression and phosphorylation of MAP 
kinase proteins, these cells clearly have been affected by the treatment with bromelain. These 
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DC have upregulated levels of maturation markers and co-stimulatory molecules when 
compared to immature cells, and parts of their RelB molecules have been re-localized to the 
nucleus, but most importantly, they do secrete more IL-12p70 than cytokine DC. These 
results indicate that bromelain might be an interesting substance that could be used as an 
additional stimulus during generation of DC, in the further search of the optimal DC 
population for use in immunotherapy.  
 
5.2 Future perspectives 
 
This study was the first to investigate the effect of bromelain on human monocyte derived 
dendritic cells. I have discovered that DC are stimulated and matured after treatment with this 
plant substrate. The mechanisms behind these effects of bromelain on the cells are still 
unknown. One possibility way could be via toll like receptors, and it might be interesting to 
examine if TLR are involved in the effect of bromelain on DC. Since bromelain is a crude 
extract we do not know exactly what it contains and how the different cells respond to this. 
Some of my experiments need to be repeated, this include additional migration/chemotaxis 
analyses, as well as further MLR to see if there exist a pattern. For future migration analyses 
we might try to use serum free X-VIVO medium to eliminate any possible migratory abilities 
caused by substances in serum. In addition to these allogeneic analyses, it would be 
interesting to investigate the T cell stimulatory capacity in an autologous setting using tumor 
specific antigens, since this is the T cell stimulatory capacity that is most important in the 
light of immunotherapy. It could be possible to analyze phosphorylation patterns for the MAP 
kinase proteins for several different time points and try to locate the optimal stimulation 
period for maximal phosphorylation values of these proteins. 
 
As a result from the experiments performed, 25µg/ml bromelain seems to be the most 
promising concentration for further use. The next step may be to analyze the effect of this 
concentration of bromelain in combination with the cytokine cocktail or other promising 
agents/substances, to see if there are any synergistic effects when combined with other 
stimulatory agents. One of the problems working with DC is the limited number of cells 
available for each experiment since these cells are not proliferating, only differentiating. Since 
the focus would be on 25µg/ml bromelain it could be possible to analyze phosphorylation 
patterns for the MAP kinase proteins at several different time points.
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